Wednesday, August 14, 2013 9:25:12 AM
In connection with the Merger Agreement, the Company entered into a stock purchase agreement (the “Purchase Agreement”) with certain private investors (the “Investors”), pursuant to which the Investors have agreed to purchase an aggregate of 7,500,000 shares of a new series of the Company’s preferred stock, par value $0.01 per share, to be designated Series B Convertible Preferred Stock (the “Series B Preferred Stock”), each share of which would initially be convertible, subject to certain conditions, into ten shares of Common Stock (the “Conversion Shares” and, together with the Series B Preferred Stock, the “Private Placement Securities”), for a purchase price of $4.00 per share of Series B Preferred Stock payable in cash, cancellation of certain indebtedness of TransEnterix or a combination thereof (the “Private Placement”). Pursuant to the Purchase Agreement, the Company may agree to issue and sell up to an additional 1,250,000 shares of Series B Preferred Stock within two weeks subsequent to the closing of the issuance and sale of the initial 7,500,000 shares. Among the Investors are Frost Gamma Investments Trust, an entity controlled by Dr. Phillip Frost, one of the largest beneficial owners of the Company’s common stock, and Dr. Jane Hsiao, the Company’s current Chairman
--------------------------------------------------------------------------------
of the Board (collectively, the “Related-Party Investors”), each of whom would acquire shares of Series B Preferred Stock in the Private Placement pursuant to the same terms, and subject to the same conditions, as those applicable to all other Investors. The Audit Committee of the Board approved the Related-Party Investors’ participation in the Private Placement. Consummation of the Private Placement is conditioned upon consummation of the Merger and certain customary closing conditions.
Recent ASXC News
- Asensus Surgical Announces St. Marianna University School of Medicine Yokohama City Seibu Hospital in Japan to Initiate Senhance Surgery Program • GlobeNewswire Inc. • 06/24/2024 10:55:00 AM
- Kuehn Law Encourages ICCH, DO, ASXC, and DPSI Investors to Contact Law Firm • PR Newswire (US) • 06/11/2024 12:04:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 06/07/2024 08:19:53 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 06/07/2024 12:50:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/07/2024 12:50:23 PM
- Asensus Surgical Announces Signing of Definitive Merger Agreement with KARL STORZ • GlobeNewswire Inc. • 06/07/2024 12:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 08:33:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 10:55:34 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 08:51:25 PM
- Asensus Surgical, Inc. Reports Operating and Financial Results for the First Quarter 2024 • GlobeNewswire Inc. • 05/14/2024 08:05:00 PM
- Asensus Surgical, Inc. Schedules First Quarter Financial and Operating Results Conference Call for May 14, 2024 • GlobeNewswire Inc. • 05/07/2024 10:55:00 AM
- Asensus Surgical Announces Sendai Tokushukai Hospital in Japan to Initiate Senhance Surgery Program • GlobeNewswire Inc. • 04/29/2024 10:55:00 AM
- Asensus Surgical, Inc. Announces Non-Binding Acquisition Proposal and Exclusivity Arrangement with KARL STORZ SE & Co. KG • GlobeNewswire Inc. • 04/03/2024 12:45:00 PM
- Asensus Surgical, Inc. Reports Operating and Financial Results for the Fourth Quarter 2023 and Full Year 2023 • GlobeNewswire Inc. • 03/21/2024 08:05:00 PM
- U.S. Index Futures Rise as Fed’s Dovish Outlook Spurs Positive Investor Sentiment; Oil Prices See Minor Declines • IH Market News • 03/21/2024 11:26:38 AM
- Asensus Surgical, Inc. Schedules Fourth Quarter and Full Year 2023 Financial and Operating Results Conference Call for March 21, 2024 • GlobeNewswire Inc. • 03/15/2024 10:55:00 AM
- Asensus Surgical to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference • GlobeNewswire Inc. • 02/28/2024 11:55:00 AM
- Asensus Surgical Celebrates 1,000 Senhance Cases Completed at Three Global Hospitals • GlobeNewswire Inc. • 02/27/2024 11:55:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 12:01:47 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 12:00:04 AM
- Asensus Surgical Announces Nagoya University Hospital in Japan to Initiate Senhance Surgery Program • GlobeNewswire Inc. • 01/16/2024 11:55:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 11:55:21 AM
- Asensus Surgical Provides Preliminary 2023 Year-End Corporate Update • GlobeNewswire Inc. • 01/08/2024 11:45:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 09:45:21 PM
- Asensus Surgical Completes In Vivo Surgeon Lab for LUNA Surgical Robotic System • GlobeNewswire Inc. • 01/04/2024 09:15:00 PM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM